Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ageless vs Direct Meds

Ageless
Graded #82

Lower grade

vs+7.9
Direct Meds
Graded #35

Higher grade

The verdict

Direct Meds takes it — 77.6/100 to 69.7/100.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDirect Meds +27
58
85
Dose & formulationAgeless +2
90
88
Clinical oversightEven
55
55
Labs & monitoringEven
78
78
FulfillmentAgeless +4
84
80
Contract termsDirect Meds +25
55
80
Ageless · left barDirect Meds · right bar

The numbers

MetricAgelessDirect Meds
WeighScore69.7/10077.6/100
GradeCC+
Scorecard rank#82#35
Semaglutide$279/mo month-to-month (the advertised "from" figures are 3-, 6- and 12-month prepays)$249/mo sublingual · $297/mo injectable
Tirzepatide$349/mo month-to-month (the advertised "from" figures are 3-, 6- and 12-month prepays)$299/mo sublingual · $399/mo injectable
CoverageVaries by stateNot publicly listed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Ageless

Graded #82 · C

FDAWarning letter issued to Lovely Meds, Inc. dba Lovely Meds in September 2025. Try Ageless's own medical-oversight page identifies Lovely Meds, Inc. as the company that operates tryageless.com. The letter concerns lovelymeds.com, does not name tryageless.com, and FDA has not closed it out. See the FDA warning-letter database.

Strengths

  • Unusually broad compounded menu — GLP-1, NAD+, sermorelin, TRT, LDN and more, in both injectable and oral formats
  • Every GLP-1 format has a real month-to-month rung as well as prepay tiers, so nobody is forced into a commitment in order to buy at all
  • Sublingual tirzepatide drops are genuinely cheaper than the injection without a commitment — $199/mo month-to-month against $349 for the shot
  • The SLIM50 code is stated as a recurring $50 discount rather than a first-month teaser that expires
  • Fully online: licensed-clinician review and discreet delivery, with upfront compounded/not-FDA disclosures

Where it loses points

  • The advertised entry prices are twelve-month rungs, not monthly rates: the hero's "from $159/mo" and the "FROM $199 / $249" cards are annual plans charged as one payment of $1,908, $2,388 or $2,988 — buying by the month costs $279 for semaglutide and $349 for tirzepatide
  • The same company sells the same semaglutide injection at two prices — a storefront catalog at $119–$229 for a month's supply as a one-time purchase, and the plan page our link resolves to at $279/mo — with no page reconciling them, and the storefront's checkout is disabled so its figures are never actually charged
  • The storefront disagrees with itself as well: for the same item its struck-through "was" anchor is $169 in one place and $229 in another
  • Sermorelin is priced four different ways across the company's own pages ($189, $126, $239–$289, $199–$299), so a figure read off one of them is not the figure the funnel charges
  • The default variant on a product page is the LOWEST dose, so any "from" price is the bottom of a dose ladder that runs up to $199–$299
  • TRT has no month-to-month rung at all — the shortest purchasable term is a three-month prepay, from $387 charged up front
  • Everything is compounded and not FDA-approved — not equivalent to brand Wegovy/Ozempic/Zepbound
  • Oral GLP-1 drops and troches lack robust absorption/efficacy evidence versus injectables
  • No published state-availability list, so coverage is only settled inside the funnel
Direct Meds

Graded #35 · C+

FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 536 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard